Showing 1-10 of 52 "Cancers and Other Neoplasms"

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This is an open-label, multicenter, phase 2 study to evaluate the efficacy and safety of oral MLN9708 in adult patients with follicular lymphoma (FL) that is relapsed and/or refractory to prior treatment. ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

Consider the cell we study in high school biology. Its structure is illustrated in the figure to the left. The nuclear material at the core of the cell is ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The PENELOPEB study is designed to demonstrate that in the background of standard anti-hormonal therapy palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women with HR-positive/HER ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Ramon Guardiola

Phone: 713.441.3958

This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, INCB050465, as monotherapy and in combination with: itacitinib (INC ... Read more >

Status: Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a multi-center, open-label Phase Ib study. The ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This multicenter, randomized, double-blind study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with ... Read more >

Status: Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Pamela Weaver

Phone: 713.441.3834

Purpose This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to subjects with recurrent high grade glioma (rHGG) who have u ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Alice Pavlak

Phone: 713..44.1.3246

This open-label, multicenter, global study is designed to determine the recommended phase 2 dose, safety, efficacy, and pharmacokinetics/pharmacodynamics of durvalumab in subjects with certain lymphoma subtypes or CLL. Globally, 253 subjects may ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some o ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Enrolling

Investigator: Brian Miles

Study Coordinator: Vivian MacDonnell

Phone: 714.441.8113

This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >

Status: Open Not Enrolling

Investigator: Orlando Diaz

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Micro Catheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures. ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast canc ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This study will evaluate whether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with HR+, HER2-, AI treated locally advanced or metastatic breast cancer who progressed on or after mTor inhibitor based trea ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies. ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory or previously untreated chronic lymphocytic ... Read more >

Status: Open Not Enrolling

Investigator: Daniel Lehane

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplati ... Read more >

Status: Open Not Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether paclitax ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously treated stage II, stage III, or stage IV ovarian ... Read more >

Status: Open Not Enrolling

Investigator: Daniel Lehane

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x- ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This is a multi-center, randomized, double-blinded, placebo controlled trial in pre-menopausal women with advanced breast cancer. ... Read more >

Status: Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a Phase Ib study assessing the maximum tolerated dose (MTD) and dose-limiting toxicities of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple negative breast cancer patients. The study will be conduc ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplati ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-negative MBC. This study has 2 phases: a dose-e ... Read more >

Status: Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC; i.e., tumors lacking expression of estrogen, pr ... Read more >

Status: Enrolling

Investigator: Daniel Lehane

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already received chemotherapy prior to surgery. </div ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Pamela Weaver

Phone: 713.441.3834

Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site pr ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Alice Pavlak

Phone: 713..44.1.3246

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Ramon Guardiola

Phone: 713.441.3958

An oral formulation of azacitidine (CC-486) has been developed and is currently in clinical trials for the treatment of hematologic and solid tumor malignancies. The oral formulation will provide an opportunity to deliver the drug daily over a m ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Pamela Weaver

Phone: 713.441.3834

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects u ... Read more >

Status: Enrolling

Investigator: Daniel Lehane

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for ap ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to ev ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The primary objective is to evaluate the safety and tolerability of IMMU-132 as a single agent administered in 3-week treatment cycles for up to 8 cycles, in previously treated patients with advanced epithelial cancer. IMMU-132 targets the TROP- ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor (HER2)-amplified BC. An open label Phase 1b clinical study (REP0111) is ongoing (enrollment completed) in fi ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and ce ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study "Master Protocol". The type ... Read more >

Status: Enrolling

Investigator: Rafik Ghobrial

Study Coordinator: Joel Cisneros

Phone: 713.441.6311

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option f ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Allison Rounds

Phone: 713.441.8389

The purpose of this study is to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Lacey Burey

Phone: 713.441.1159

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exem ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this study is to evaluate the Pathological Complete Response (pCR) of the breast when trastuzumab emtansine (TDM-1) plus Lapatinib plus Abraxane is combined in newly diagnosed HER2 positive breast cancer. ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This open-label, single-center study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) to Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer. Patients will receive Abraxane on Day 1 of ... Read more >